REHOVOT, Israel, Aug. 23, 2017 -- Evogene Ltd., (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity, announced today that the R&D director of its Ag-Chemicals activity area, Dr. Boaz Inbal, will present the company’s biology-driven computational chemistry platform, including proprietary Artificial Intelligence predictive models, and novel product pipeline.
Dr. Inbal will be presenting at the Asian Pacific Weed Science Society Conference taking place September 19th-22nd, 2017 in Kyoto, Japan. Dr. Inbal’s presentation is scheduled for September 20th (Wed) at 14:30.
In his presentation, Dr. Inbal will describe Evogene’s unique approach for biology-driven discovery and optimization of novel pesticides, addressing market challenges of increasing resistance and product safety. Evogene’s computational platform is utilized in the collaboration with BASF, as well as in internal programs and other collaborations.
South East Asian markets are important Agriculture growth markets, as they consist of more than a third of the world’s population. Evogene's unique approach complements the growing need for Ag-Innovation in these markets.
About Evogene Ltd.:
Evogene (NASDAQ:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
Forward Looking Statements:
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Nir Zalik IR/PR Manager E: [email protected] T: (+972)-8-931-1963


Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



